In summary, our data provide evidence that PR1 leukemia antigen-specific CTL-mediated anti-tumor immunity after IFN withdrawal may contribute to continued CR in the absence of subsequent treatment, including withdrawal of IFN. The gene discussed is IFNA1; the disease is neoplasm.